728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Abstract

IMC-F106C is the first TCR bispecific protein targeting CD3 and PRAME, the most broadly expressed cancer testis antigen, which is homogenously expressed in multiple tumors (eg, lung, ovarian, endometrial, melanoma, breast). ImmTAC bispecifics redirect polyclonal T cells to target intra/extracellular cancer proteins, as validated by tebentafusp (tebe; gp100×CD3 ImmTAC) with an overall survival benefit in metastatic uveal melanoma (mUM).